Literature DB >> 8914972

Structural characterization of recombinant domain II of the basement membrane proteoglycan perlecan.

M Costell1, T Sasaki, K Mann, Y Yamada, R Timpl.   

Abstract

Mouse perlecan domain II (325 residues), consisting of four cysteine-rich LA modules, one IG module and a link region, was obtained in purified form from a stably transfected mammalian cell clone. Rotary shadowing electron microscopy demonstrated a globular domain connected to a short rod-like segment of variable length. This suggested that tandem arrays of LA modules form rod-like elements. Folding into a native structure was indicated by the sharing of immunological epitopes with tissue perlecan, a CD spectrum demonstrating 37% beta structure and a limited susceptibility to proteolysis. The domain also showed N-glycosylation of a single acceptor site and 7-8 O-linked oligosaccharides. The latter were located mainly in the link region within proline-rich sequences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914972     DOI: 10.1016/0014-5793(96)01082-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.

Authors:  Ronald R Gomes; Mary C Farach Carson; Daniel D Carson
Journal:  Connect Tissue Res       Date:  2003       Impact factor: 3.417

2.  Basement membrane and stroke.

Authors:  Yao Yao
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-18       Impact factor: 6.200

3.  Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability.

Authors:  Gerhard Sengle; Robert N Ono; Takako Sasaki; Lynn Y Sakai
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

4.  Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.

Authors:  Margaret M French; Ronald R Gomes; Rupert Timpl; Magnus Höök; Kirk Czymmek; Mary C Farach-Carson; Daniel D Carson
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

5.  Induction of perlecan expression and neural cell proliferation by FGF-2 in the developing cerebral cortex: an in vivo study.

Authors:  Farhad Mashayekhi; Mahdiyeh Sadeghi; Farzad Rajaei
Journal:  J Mol Neurosci       Date:  2010-06-01       Impact factor: 3.444

6.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

7.  The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis.

Authors:  Yu-Xin Xu; David Ashline; Li Liu; Carlos Tassa; Stanley Y Shaw; Katya Ravid; Matthew D Layne; Vernon Reinhold; Phillips W Robbins
Journal:  J Lipid Res       Date:  2014-12-20       Impact factor: 5.922

Review 8.  Basement membrane and blood-brain barrier.

Authors:  Lingling Xu; Abhijit Nirwane; Yao Yao
Journal:  Stroke Vasc Neurol       Date:  2018-12-05

9.  Perlecan controls neurogenesis in the developing telencephalon.

Authors:  Amparo Girós; Javier Morante; Cristina Gil-Sanz; Alfonso Fairén; Mercedes Costell
Journal:  BMC Dev Biol       Date:  2007-04-05       Impact factor: 1.978

Review 10.  Modular Proteoglycan Perlecan/HSPG2: Mutations, Phenotypes, and Functions.

Authors:  Jerahme R Martinez; Akash Dhawan; Mary C Farach-Carson
Journal:  Genes (Basel)       Date:  2018-11-16       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.